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(Received for publication, October 21, 1941) Although the antibacterial action of sulfonamide compounds upon certain pathogenic microorganisms is now generally recognized, the effect of these drugs upon the immunological response of the animal or human host has not been completely elucidated. In view of the value of sulfonamides in the therapy of pneumonia and other diseases caused by pneumococci and because of the essential contribution of immunity to recovery from such infections, it seemed desirable to investigate further the action of sulfapyridine upon the immune processes.
In response to the antigenic stimulus of pneumococcus the tissues of man and certain animals are capable of elaborating type specific antibodies which circulate in the blood and can be determined by the appropriate techniques. In experimental animals it is also possible to recognize the occurrence of active immunity as indicated by increased resistance to homologous infection which may be present before and may persist after the period when circulating antibodies are detectable. In the process of spontaneous recovery from pneumococcal infection disposal of the invading microorganisms by the phagocytic ceils cannot be accomplished without the development of a specific immune response.
The sulfonamide compounds exert a direct bacteriostatic effect upon various microorganisms. For these drugs to be effective therapeutically, however, the participation of specific humoral and cellular reactions of the host are essential requirements. The question of whether, in addition to their direct actions upon the bacteria, these compounds may not also exert an effect upon the defense mechanism of a host has been subjected to both experimental and clinical investigation. It has been demonstrated in mice injected intraperitonally with pneumococci that the suffonamide drugs do not affect the mobilization or activity of the phagocytic cells (1, 4) . Although no evidence has been produced to show that these drugs stimulate or accelerate the process of antibody formation, the assumption that they exert no effect on the immune mechanism has not been unreservedly accepted.
In 1937 Buttle (2) observed that mice after recovery from infection with Pneumococeus Type I following treatment with the benzylidene Schiff's Base of 4:4' 77 diaminodiphenylsulfone were immune to reinfection with organisms of the homologous type. In the following year Whitby (3) confirmed this observation in mice treated with sulfapyridine. McIntosh and Whitby (4) found that at the end of 1 week mice which had survived 10,000 lethal doses of Pneumococcus Type I after oral treatment with sulfapyridine were completely immune to reinfection with a million fatal doses of pneumococci of the homologous type. This immunity was related quantitatively to the infective dose and was type specific. An inocuhm of 1 million heat-killed pneumococci stimulated in vaccinated mice a degree of immunity comparable to that induced in mice following recovery under drug therapy from an otherwise fatal infection with 10,000 living pneumococci. In the latter instance the surviving animals on reinoculation were immune to an amount of virulent culture 100-fold greater than that used in the primary infection. The active immunity induced by vaccination or resulting from infection was demonstrable within 3 days. By the 4th or 5th day immunity was usually solid, and on the latter day the sera conferred passive protection on other mice. In the sera of mice immunized with
Eberthella typhosa agghtinins were demonstrable by the 3rd day and increased in titer between the 4th and 7th days irrespective of whether or not sulfanilamide had been administered. These authors concluded that "the administration of sulphonamide drugs has no stimulating action on the body defenses, nor does such administration affect the quality, quantity, or speed of production of recognized specific antibodies." Experimental confirmation of Whitby's observation was reported in 1939 by CaUerio (5) and MacLeod (6) . MacLeod compared the survival rate following sulfapyridine therapy with the immune response in untreated animals, employing Pneumococcus Type I, a good antigen, and Pneumococcus Type III, a relatively poor antigen. He found that in mice infected with 10 -2 cc. of a virulent culture of Pneumococcus Type I and treated with sulfapyridine, 95 to 100 per cent survived, whereas in mice similarly treated but infected with Type III pneumococci less than 10 per cent survived. In two groups of untreated mice immunized respectively with comparable doses of heat-killed pneumococci of Types I and III and infected 5 days later with 1,000 fatal doses of a virulent culture of the corresponding type, 95 to 100 per cent of those in the Type I group were immune while none of the Type III mice survived. An apparent correlation was observed not only between the survival rate and the relative antigenicity of the respective types of pneumococci, but also between the differences in the time required for the development of antibodies and the length of time during which it was necessary to continue sulfapyridine treatment.
Larson, Bieter, and Levine (7, 8) demonstrated that rabbits which recovered from intradermal infection with Pneumococcus Type II following treatment with sulfapyridine were highly resistant to reinfection with the homologous type of organism 30 or more days later.
In the sera of patients with pneumococcal pneumonia the appearance of type specific antibodies at or about the time of spontaneous recovery is a well recognized phenomenon. However, in patients treated with sulfonamide drugs the appearance of these antibodies does not necessarily coincide with the defervescence frequently observed early in the course of illness.
Edwards, Kirch~r, and Thompson (9) tested 26 pneumonia patients treated with sulfapyridine for the development of dermal reactions to homologous type specific capsular polysaccharide as well as for the presence in their sera of type specific agglutinins. They concluded from the results of their observations that the immune responses which occur naturally in the course of untreated pneumonia are not affected by drug therapy.
Wood and Long (10) demonstrated specific protective antibodies in the sera of 10 out of 12 patients with pneumococcal pneumonia who were treated with sulfapyridine. They concluded that the antibody response in patients treated with sulfapyridine is similar to that observed in untreated patients.
Finland, Spring, and Lowell (11) studied the bactericidal power of whole blood as well as the development of homologous type specific agglutinins and mouse protective antibodies in the sera of a large number of patients with pneumococcal pneumonia treated with sulfapyridine. These investigators reported that mouse protective antibodies and agglutinins were rarely demonstrable in patients' blood before the 6th or 7th day although defervescence frequently occurred earlier. They concluded that the antibody response in patients treated with sulfapyridine was comparable in all respects to that observed in spontaneous recovery.
Fox, Rosi, and Winters (12) determined the time of appearance of specific antibodies in the sera of 50 adult patients treated with sulfapyridine. In all patients with proven pneumococcal pneumonia type specific agglutinins were demonstrable in the blood at some time in the course of illness. These same authors reported subsequently (13) that in a larger series 90 per cent of the patients developed type specific agglutinins by the end of the 2nd week of illness and that 50 per cent of those tested gave true positive skin reactions to the homologous type specific polysaccharide. Kneeland and Mullikin (14) tested the sera of 19 patients with pneumonia who were treated with sulfapyridine. They observed that positive precipitin reactions to the homologous capsular polysaccharide appeared in the sera of only four of their patients upon recovery. In a subsequent paper these authors (15) reported that type specific precipitins were detectable in the sera of only 8 of 30 sulfapyridine-treated patients as compared with 16 of 21 patients treated with sulfathiazole. They suggested that sulfapyridine by its action upon the invading microorganism diminishes the stimulus to antibody formation, whereas sulfathiazole, which they considered a less powerful bactericidal agent, exerts this effect to a lesser degree.
Bukantz and de Gara (16) demonstrated the presence of homologous type specific precipitins during recovery in the sera of nineteen of sixty patients with pneumonia who were treated with sulfapyridine.
In the animal experiments thus far reported, with the exception of those of McIntosh and Whitby, tests for resistance to homologous reinfection have been made at a time when immunity had reached or passed the peak of maximal response. In clinical studies the detection of circulating type specific antibody is necessarily limited by the methods which can be employed. The free circulating antibodies detectable in vitro by serological techniques probably repre-sent an excess over the amount actually required for the ini~ation of recovery, except in those instances in which a severe infection overwhelms the total defense reactions of the patient. The results obtained by serological methods represent the summation of so many interrelated factors that any direct effect of sulfonamide therapy upon the specific immune response is necessarily obscured.
The present study was undertaken in order to determine whether or not the administration of a sulfonamide drug has a direct effect upon the development of immunity and to compare the relative sensitivity of various techniques used in measuring immunity, such as tests of active resistance to reinfection and the serological methods for determining the presence of circulating type specific antibodies. In order to standardize conditions as much as possible it seemed advisable to concentrate attention upon the immune response to a potent antigenic stimulus during the early stages. For this purpose Pneumococcus Type I was selected as the test organism, the rabbit as a suitable animal host, and sulfapyridine as a representative sulfonamide drug. These experimental conditions provided an opportunity to employ a highly virulent organism with potent antigenic capacity, an an~mnl at once susceptible to infection with the organism and readily immunized by it, and a chemotherapeutic agent highly effective against the organism while not excessively toxic for the host.
EXPERIMENTAL
Rabbits were given intravenously a single immunizing injection of heat-killed Pneumococcus Type I. Approximately half of the vaccinated animals received sulfapyridine. Administration of the drug was started prior to vaccination, and was continued during the period when immunity was developing. The drug was discontinued before testing for active immunity by intradermal inoculation withPneumococcus Type I.
Comparable groups of rabbits which had and which had not received sulfapyridine were injected intradermaUy with virulent Pneumococcus Type I, 48, 72, and 96 hours after vaccination. The immunizing injection was given to the respective series of animals on successive days so that all of the vaccinated rabbits in each experiment could be infected simultaneously.
The degree of immune response which had developed 48, 72, and 96 hours after vaccination was estimated in the sulfapyridine-"treated" and "untreated" rabbits 1 on the basis of their resistance to intradermal infection as well as by the presence 1 For convenience the terms "treated" and "untreated" will hereafter be used to designate respectively those rabbits which received sulfapyridine and those to which no drug was given. It should be emphasized, however, that in the "treated" animals administration of sulfapyridine was in each instance discontinued 24 to 36 hours prior to infection and that none of the rabbits received chemotherapy following the intradermal inoculation.
in their sera of circulating type specific precipitins, agglutinins and mouse protective antibodies. For these determinations blood was drawn from each rabbit prior to vaccination and at appropriate intervals thereafter up to the time of intradermal infection.
Culture.--A virulent strain of Pneumococcus Type I (S V-I) was used both for preparing the vaccines and for intradermal injection. The virulence of this strain was enhanced and maintained by frequent passage in normal rabbits so that 0.2 cc. of a 1/500,000 dilution produced a fatal infection when injected intmdermally.
Preparation of Vaccines.--The organisms from an 8 to 10 hour plain broth culture of Pneumococcus Type I were collected by centrifugation and resuspended in physiological salt solution equivalent in volume to 1/10 that of the original culture. The organisms were immediately killed by heating the bacterial suspension at 60°C. for 30 minutes in a water bath and then cultured to control sterility. A freshly prepared vaccine was used in each experiment. During the 48 hour period of use the vaccines were stored in the ice box and in all instances the bacterial cells retained their Grampositive character.
Immunization.--"ChinchiUa" rabbits weighing in the neighborhood of 2,000 gm., with a maximum variation of 1,560 to 2,500 gm. were kept under observation for a period of at least one week before use. Immunization was carried out by giving each rabbit a single intravenous iniection of 1.0 cc. of vaccine corresponding to 10.0 cc. of original culture.
Sulfapyridine Administration.--Tablets of sulfapyridine (0.5 gin. Merck) were triturated in a mortar with 0.75 per cent solution of gum tragacanth so that 4.0 cc. of the resulting suspension contained 0.5 gin. of sulfapyridine. The drug was administered by stomach tube in doses of 0.5 gm., the 4.0 cc. of suspension being followed immediately by an equal volume of water to wash out the tube and insure passage of the whole amount into the stomach. Administration was begun prior to immunization, continued at intervals of 8 to 12 hours for approximately three days, and discontinued 24 to 36 hours before infecting the animals intradermally. The total dose of sulfapyridine given to each animal was 4.5 gin. with the exception of four rabbits which received reduced dosage because of toxic symptoms. Blood for sulfapyridine determinations was drawn at daily intervals during and after the course of drug administration until iust prior to intradermal infection. The determinations were made according to the technique of Bratton and Marshall (17) employing a photoelectric colorimeter.
Determination of Type Specific Immunity by Means of Intradermal Infecthm.--
At intervals of 48, 72, and 96 hours after injection of immunizing antigen, both the sulfapyridine treated and untreated groups of rabbits together with an adequate number of normal control animals were infected intradermally with a virulent culture of Pneumococcus Type I according to the method of Goodner (18) . The infective dose, 0.2 cc. of a 1:5,000 dilution of an 8 to 10 hour blood broth culture, was invariably fatal for the controls.
The degree of immunity was estimated by comparing the clinical course of the experimental intradermal infection in the immunized and control animals. The observations included rectal temperatures twice daily, the severity and progression of the dermal lesions, and the results of quantitative cultures of the blood obtained daily from the marginal ear veins. Animals which died were examined at autopsy and cultures were made of the heart's blood.
Determination of Circulating Antibodies. Precipitins.--Precipitin tests were carried out using 0.3 cc. respectively of undiluted rabbit serum and a 1:25,000 dilution of the acetylated pneumococcus Type I capsular polysaccharide. After thorough mixing of the contents, the tubes were incubated at 37°C. for 2 hours, refrigerated overnight, and read the following morning.
Agglutinins.--Tests for type specific agglutinins were carried out using serial dilutions of each serum. Formalin-killed cells of Pneumococcus Type I, suspended in a volume of saline equal to that of the original culture were employed. To 0.3 cc. of the serum dilutions, 0.3 cc. of antigen was added and after thorough mixing the tubes were incubated at 37°C., refrigerated overnight and read the following morning.
Mouse Protective Antibodles.--The sera of rabbits before immunization and at intervals of 48, 72, or 96 hours thereafter were tested in mice for protective antibodies by titrating dilutions of culture against a constant amount of serum.
The cultures of Pneumococcus Type I (S V-I) used in protection tests were of such virulence that the intraperitoneal injection of 10 -s cc. invariably proved fatal. The protection test was considered negative if 0.2 cc. of serum failed to protect 2 of 3 mice against 10 -6 cc. of culture. Sera of rabbits which afforded protection to mice infected with 10 -6 cc. (100 ~.L.D.) of culture were also tested against 10 -5 cc. (1000 M.L.D.). Amounts of culture greater than this were not used.
Blood Levels of Free and A cetylated Sulfapyridine.--Blood drawn at intervals
during the period of sulfapyridine administration indicated satisfactory absorption of the drug. The blood levels of free and acetylated sulfapyridine, however, varied greatly in different animals under the same conditions. During the period of administration the highest concentration of free drug noted was 15.0 nag. per cent, the lowest 0.5 rag. per cent. The highest concentration of the acetylated compound was 71.2 mg. per cent, the lowest 4.3 mg. per cent. Although the blood level of free sulfapyridine dropped fairly rapidly in the interval between doses and after administration was discontinued, the acetylated form was eliminated much more slowly. In order that there should be little or no sulfapyridine remaining in the blood at the time of intradermal infection it was found necessary to discontinue administration of the drug 24 to 36 hours prior to infection. Determinations made 24 hours before intradermal infection showed that only 9 of the 34 animals still had free circulating sulfapyridine, although at this time the blood of all of the 22 rabbits tested for the acetylated compound showed its presence in amounts ranging from 1.3 to 71.2 rag. per cent.
Determinations made immediately before infection upon the blood of 30 immunized rabbits which received sulfapyridine showed the presence of the free drug in 3 instances. The blood of only one of these animals contained a measurable quantity (1.6 rag. per cent). On the other hand, the acetylated compound was present in the blood of 11 out of 26 rabbits immediately before infection. The levels varied between 0.5 mg. and 5.7 rag. per cent. That these residual amounts of sulfapyridine remaining in the blood at the time of intradermal infection exerted no significant mitigating effect upon the course of the disease is indicated by the following observations. Sulfapyridine was present at the time of intradermal infection in the blood of three Of the four treated animals which died. Furthermore, the fatal course of infection in four sulfapyridine treated rabbits which were not immunized, was essentially the same as that in the normal controls. Crystals of acetylated sulfapyridine were found at autopsy in the bladder and renal pelves of two rabbits which developed overwhelming bacteremia.
Toxic Effects of Sulfapyridine.--Almost all of the rabbits which received sulfapyridine showed some evidence of intoxication during the course of drug administration. This was manifested by varying degrees of anorexia, weakness, and loss of weight. Sulfapyridine intoxication may have been a contributory factor in the death of one rabbit which was infected 72 hours after immunization and died on the 4th day after a mild illness unaccompanied by bacteremia. Postmortem examination revealed a loss of 300 gm. in weight, a minimal skin lesion showing evidence of healing and no gross abnormalities of the organs. Analysis of the bladder urine disclosed the presence of acetylated sulfapyridine in a concentration of 2.5 mg. per cent.
It seems evident that the amount of drug used in these experiments was about the maximum that could be tolerated by the animals over the period of administration. 
Effects of Intravenous

Characteristics of the Disease Produced by Intradermal Infection.--The disease
produced in rabbits by the intradermal injection of Pneumococcus Type I has been thoroughly described by Goodner (18, 19) . The cotrrse of the illness in the 26 control animals corresponded closely to his description. The disease was characterized by high sustained fever, extensive dermal lesions, progressive bacteremia, and an invariably fatal termination within 6 days. In immunized rabbits modifications of these findings were progressively more in evidence as the interval between immunization and infection was increased. As a basis for the estimation of active immunity, the effects of infection at different intervals after immunization in rabbits which received sulfapyridine are compared with the reactions of animals to which no drug was given. These data are presented graphically in Text- fig. 1 . Characteristics of the disease produced by intradermal infection with Pneumococcus Type I in rabbits previously immunized with a heat-killed suspension of organisms of the homologous type. Immunization was carried out by a single intravenous injection of a suspension of heat-killed Pneumococcus Type I equivalent to 10 cc. of original culture. Intradermal infection was initiated by the injection of 0.2 cc. of a 1:5000 dilution of an 8 to 10 hours rabbit blood broth culture of virulent Pneumococcus Type I. Solid black shading indicates the number of days during which a rabbit's temperature was elevated to 104 ° or above. Absence of shading indicates absence of fever. Plus signs represent the occurrence of dermal lesions graded in severity from + to represent a minimal lesion to + + + + indicating one of maximal intensity. Minus sign indicates that no lesion developed. Cross hatching represents the incidence and duration of bacteremia. The small numbers in the cross hatched areas indicate the bacterial colony counts per cubic centimeter. Cultures of the blood which proved sterile are indicated by the symbol 0. D indicates animals which died, and with but one exception is placed so as to designate the day of death. Rabbit 7-11 died on the llth day with persisting bacteremia.
The criteria for these comparisons include the incidence and duration of fever, the occurrence and severity of the lesions, the degree and duration of bacteremia, as well as the number of fatalities and the time of their occurrence. Temperatures of 104°F. or above were considered abnormal. The degree of temperature elevation is not included in this report since in most instances high fever continued until the time of death or recovery. The severity of lesions has been designated by the symbols + to + + + +, to represent the gradations of dermal involvement varying from a small circumscribed tuberculin-like reaction to an extensive area of dependent inflammatory edema with ecchymosis and necrosis. The most severe reactions were usually observed in the unvaccinated control animals, but not invariably, since several died before the lesions appeared to be fully developed. Evidences of incipient healing of the dermal infection usually paralleled other indications of recovery. The rate of healing seemed to depend upon the extent and severity of the lesions. The outcome of the infection, however, could not be predicted from the severity of the local inflammatory process, for many of the animals infected 48 hours after vaccination had lesions of maximal intensity but ultimately survived.
In all of the control animals, and with but two exceptions among the 23 vaccinated rabbits which developed bacteremia, cultures of the blood taken 24 hours after infection yielded growth of Pneumococcus Type I. In most of the vaccinated rabbits, notably those with low initial colony counts, cultures of the blood became sterile coincidentally with other evidences of recovery, whereas in some of the vaccinated and in all of the unvaccinated rabbits, bacteremia persisted and progressively increased until the time of death. From seven of the eight fatalities among the 62 immunized rabbits, Pneumococcus Type I was isolated in cultures of the blood taken during life or at autopsy. The single exception was the rabbit mentioned above which may have died of sulfapyridine intoxication.
Non-Immunized Rabbits.--In the 26 control animals which received no sulfapyridine the infection followed a uniformly fatal course. Included in this number are those rabbits which received 1/10 or 1/100 of the inoculum employed routinely in infecting the vaccinated animals. High fever persisted usually until the time of death and the lesions were characteristically of maximal intensity. Cultures of the blood taken 24 hours after infection yielded from three to myriad colonies per cubic centimeter, and in every instance overwhelming blood stream invasion occurred prior to the invariably fatal termination within 6 days. In the four unvaccinated rabbits which received sulfapyridine the course and termination of the disease were identical. -fig. 1 .) Ten rabbits which received preliminary administration of sulfapyridine and ten which did not were infected 48 hours after immunization. As shown in Text- fig. 1 all of the untreated rabbits and all but two of those treated with the drug developed fever which lasted from 1 to 5 days, averaging about 3 days in the febrile animals of both groups. The lesions varied in severity from ++ to ++++ in both groups. On the whole the intensity of the lesions was perhaps a little less severe in the treated than in the untreated animals. However, eight of the rabbits in each group had positive blood cultures 24 hours after infection. Although the severity of illness in most of the rabbits was such that death seemed imminent over a period of several days, only two animals from each group ultimately succumbed, three within 4 days and one on the 11th day following persistent bacteremia. Immunization.--(Text-fig. 1.) In the ten treated and ten untreated rabbits which were infected 72 hours after immunization the manifestations of infection were considerably less than in the comparable groups of animals infected 24 hours earlier. Although fever occurred in every instance it was of shorter duration, averaging about 1{ days in the untreated and 2½ days in the treated animals. The severity of the lesions was also less intense averaging about + + in both groups with extreme variations of + to ++++.
Rabbits Infected 48 Hours after Immunization.--(Text
Rabbits Infected 72 Hours after
Bacteremia occurred in four of the untreated rabbits of which two died, and in three of the treated animals of which one died. One treated rabbit which did not have bacteremia died on the 4th day of illness. -fig. 1.) Half of the rabbits infected 96 hours after immunization, whether treated or untreated, seemed to be unaffected by the same inoculum of Pneumococcus Type I producing severe disease in animals infected after shorter intervals. Only four of twelve untreated and three of ten treated rabbits developed fever. The average duration was 2 days in each group. Lesions occurred in five animals of each group and were for the most part of minimal intensity with individual variations in severity to +++.
Rabbits Infected 96 Hours after Immunization.--(Text
None of these animals developed bactermia and all survived.
Active Immune Response at Different Intervals Following Immunization.--In
the immunized rabbits manifestations of the disease produced by intradermal infection were progressively less severe as the interval between immunization and infection was increased. The enhancement of resistance to infection in animals which had not received sulfapyridine could be explained only on the basis of an immune response to vaccination. Likewise, in the animals which received sulfapyridine there was no evidence to contradict this assumption. In order to compare the degree of active immunity in the respective treated and untreated groups of animals, and thereby determine whether or not the response in treated animals was affected by drug administration, a modification of the classification devised by Goodner (19) has been employed. Immunized rabbits which showed all the characteristics of the disease invariably noted in the controls, including a fatal termination, were considered to have no immunity. Those which showed no manifestations of disease were re- Fever, lesion, bacteremia, and death. Fever, lesion, bacteremia, survived. Fever and lesion, no bacteremia, survived. Minimal lesion, no fever, no bacteremia, survived. No evidence of disease, survived. All of the control animals had 0 immunity. ~Only 2 animals did not fit readily into these categories: (1) moderate lesion and bacteremia, no fever, survived; (2) fever and lesion, no bacteremia, died. the designated categories. Since all of the unvaccinated control animals showed no immunity they have not been included in the chart.
It is evident that as early as 48 hours after immunization most of the treated and untreated rabbits had some degree of resistance to intradermal infection. This is indicated chiefly by the fact that 80 per cent of the animals in both groups survived. The immunity was of a low order, however. 60 per cent of the surviving animals of both groups had initial bacteremia, and their degree of immunity has therefore been classified as of grade I.
When infection was deferred until 72 hours after vaccination there was an appreciable enhancement of the active immune response. 80 per cent of these animals, both treated and untreated, survived. 60 per cent of the surviving rabbits in both groups did not develop bacteremia and their degree of immunity is classified as of grade IL When rabbits were infected 96 hours after vaccination, bacteremia never occurred and little or no disease resulted. Approximately half of the animals, 50 per cent in the sulfapyridine treated and 58 per cent of the untreated group showed complete immunity classified as of grade IV. The remainder also showed a pronounced immune response estimated as of grades II or III.
Although differences in the active immune response of animals infected at varying intervals following immunization are quite striking, comparison of the corresponding sulfapyridine treated and untreated groups shows no such disparity. At each interval following vaccination the distribution of treated and untreated animals according to their relative grade of immunity to intradermal infection is practically identical. It is quite evident that under the conditions of the experiment sulfapyridine exerted no appreciable effect upon the early development of active immunity. In an additional experiment rabbits failed to show any resistance to intradermal infection with virulent Pneumococcus Type 1 48 hours after preliminary vaccination with a suspension of heat-killed "rough" organisms derived from Pneumococcus Type II. This indicates that the early immune response to homologous vaccination is type specific in nature and not the result of a non-specific enhancement of resistance.
Occurrence of Demonstrable Circulating Antibodies in the Sera of Immunized
Rabbits.--Sera obtained from rabbits prior to injection of vaccine and at intervals of 48, 72, and 96 hours thereafter were tested for circulating type specific precipitins, agglutinins, and mouse protective antibodies. Sera obtained from animals used for determinations of active resistance to intradermal infection as well as sera from a number of similarly vaccinated but uninfected rabbits were examined. The results of these observations are shown in Text- fig. 3 .
Tests for circulating antibody in the sera of vaccinated rabbits which did not receive sulfapyridine were, with but one exception, negative until 96 hours after the intravenous immunization with Pneumococcus Type I. The serum of one rabbit obtained 72 hours after vaccination, protected mice against 10 -s cc. of pneumococcus culture whereas serum from the same animal 24 hours earlier conferred no protection. This rabbit was not one of those tested for resistance to intradermal infection. Of the sera obtained from 22 rabbits 96 hours after immunization, 18 (82 per cent) protected mice against an infecting dose of 10 --e cc. (100 M.L.D.) and all but one of them against 10 -5 cc. (1000 M.L.D.) Of pneumococcus culture. In thirteen (59 per cent) of these sera type specific agglutinins were also detectable, but in low titer of 1:2 or 1:4. Type specific precipitins were observed in but two (17 per cent) of the twelve sera tested and in these instances the reactions were only faintly positive.
Similarly, circulating antibody could not be detected until 96 hours after vaccination in any of the sera from rabbits which had received sulfapyridine. Of the fourteen sera tested after this interval twelve (86 per cent) showed mouse protective antibodies. In all but one instance the mice were protected TExT-Fro. 3. Circulating antibodies in the sera of rabbits at different intervals following immunization. *P indicates the presence of type specific precipitins with the acetylated polysaccharide of Pneumococcus Type I in a dilution of 1:50,000. A indicates the presence of type specific agglutinins of Pneumococcus Type I. MP indicates the protection of mice against an intraperitoneal injection of at least 10 -ecc. virulent Pneumococcus Type I by 0.2 cc. of serum. ~To these totals may be added the number of those sera which showed no antibody 72 hours after vaccination and therefore presumably contained no demonstrable antibody 24 hours earlier. Six (43 per cent) of the fourteen sera contained type specific agglutinins. The highest titer was 1:8 in one instance. Positive precipitin reactions with the type specific capsular polysaccharide noted in only three (33 per cent) of the ten sera tested were faint and equivocal.
From these observations it is seen that tests for circulating antibodies usually did not reveal the development of immunity until 4 days after intravenous injection of vaccine and at least 2 days after active resistance to intradermal infection was demonstrable. Antibodies could be detected only in the sera of rabbits which had a relatively high degree of active immunity as indicated by resistance to intradermal infection. The findings are practically identical in the treated and untreated groups of animals indicating that the early de-velopment of circulating antibodies as well as the early development of active resistance is not influenced by the administration of sulfapyridine.
DISCUSSION
It is evident from the experimental data that the administration of sulfapyridine has no appreciable effect upon the immune response in rabbits following a single intravenous injection of heat-k~led suspension of Pneumococcus Type I.
Of particular significance is the fact that active immunity, as indicated by resistance to intradermal infection, was present 48 hours before any appreciable immune response could be detected by tests for circulating antibody. 96 hours after vaccination, when antibodies were first demonstrable in the sera, all of the animals tested were almost solidly immune to intradermal infection.
Of the techniques employed for the determination of circulating antibody, the mouse protection test was found to be the most sensitive, revealing the presence of antibody in approximately twice as many instances as did the test for agglutinins or precipitins.
The precipitin reaction, although an exquisitely sensitive method for the detection of minute amounts of capsular polysaccharide, is less satisfactory than the mouse protection and agglutination tests for the purpose of demonstrating small amounts of antibody. As the precipitate which forms the basis of this reaction is composed almost entirely of antibody, small amounts of antibody may fail to produce a visible reaction with varying dilutions of antigen although in the presence of adequate antibody the reaction with antigen in dilution as high as 1 : 5,000,000 may yield a visible precipitate. Furthermore, when used to test the sera of patients with pneumococcal pneumonia the precipitin reaction introduces another possible factor of error. If the preparation of capsular polysaccharide employed is contaminated with even a trace of the pneumococcus C polysaccharide the reaction of the latter substance with the C reactive protein of acute phase serum may be misinterpreted as an indication of the presence of type specific antibody (20, 21) .
In man studies comparable to those which can be carried out in experimental animals are not feasible. Because of the many variables existing in the patient with pneumococcal pneumonia it would be impossible to conclude from the failure to demonstrate circulating type specific antibody that resistance to infection had not developed or that administration of a sulfonamide drug had affected the development of immunity.
Either failure to produce sufficient circulating antibody or the removal of free antibody by combination with circulating antigen could preclude the detection of antibody. In any event, positive results indicate only that an excess of antibody is present, whereas negative results may signify merely that such an excess cannot be demonstrated by the techniques available.
Experimental observations, however, point clearly to the fact that a considerable type specific immune response to pneumococcus develops rapidly and may be adequate to protect against infection in the absence of demonstrable circulating antibody. Although the various types of pneumococci vary in their ability to stimulate antibody formation it seems unlikely that the sulfonamide drugs exert different effects upon this particular property in different types of pneumococcus. From the present study it appears that the development of immunity in response to a specific antigenic stimulus proceeds according to the effectiveness of the stimulus irrespective of whether sulfapyridine has been administered. SIY~MARY 1. Sulfapyridine, administered to rabbits during the period of developing immunity after a single intravenous injection of heat-killed Pneumococcus Type I, exerted no influence upon the immune response.
2. Active immunity as indicated by increased resistance to homologous intradermal infection was present 48 hours after the immunizing injection and 2 days before circulating type specific antibodies were detectable.
3. Of the serological techniques employed for the detection of circulating antibody the mouse protective test yielded the highest percentage of positive results followed in order by tests for type specific agglutinins and precipitins, the latter being least satisfactory for the detection of small amounts of antibody.
CONCLUSION
The experimental findings lend further support to the view that, in man, effective therapy of pneumococcal infections with sulfonamide drugs is intimately associated with the development of active immunity.
